• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?

作者信息

Tanda M L, Piantanida E, Masiello E, Cusini C, Bartalena L

机构信息

Endocrine Unit, ASST dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Viale Borri, 57, 21100, Varese, Italy.

出版信息

J Endocrinol Invest. 2019 Mar;42(3):351-352. doi: 10.1007/s40618-019-01015-8. Epub 2019 Feb 4.

DOI:10.1007/s40618-019-01015-8
PMID:30719623
Abstract
摘要

相似文献

1
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy?糖皮质激素与其他免疫抑制药物联合使用能否减少中重度活动性格雷夫斯眼病患者的糖皮质激素累积剂量？
J Endocrinol Invest. 2019 Mar;42(3):351-352. doi: 10.1007/s40618-019-01015-8. Epub 2019 Feb 4.
2
Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].考虑到欧洲 Graves 眼病专家组（EUGOGO）的建议，优化中重度和活动型甲状腺眼病的治疗[Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)]。
Endokrynol Pol. 2022;73(4):756-777. doi: 10.5603/EP.a2022.0040.
3
Current and Emerging Treatment Strategies for Graves' Orbitopathy.格雷夫斯眼病的当前和新兴治疗策略。
Drugs. 2019 Feb;79(2):109-124. doi: 10.1007/s40265-018-1045-9.
4
What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?对于糖皮质激素治疗失败的中重度和活动期 Graves 眼病，该如何治疗？
Clin Endocrinol (Oxf). 2010 Aug;73(2):149-52. doi: 10.1111/j.1365-2265.2010.03783.x. Epub 2010 Feb 10.
5
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?静脉注射糖皮质激素的早期反应能否预测中重度活动性格雷夫斯眼眶病患者的最终结局？
J Endocrinol Invest. 2017 May;40(5):547-553. doi: 10.1007/s40618-017-0608-z. Epub 2017 Feb 7.
6
Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.甲状腺切除术后和最大剂量静脉注射甲基强的松龙治疗后托珠单抗治疗严重和活动期格雷夫斯眼病的疗效。
Acta Med Indones. 2023 Oct;55(4):475-477.
7
Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.Graves 眼病活动期和中重度患者的治疗进展。
Lancet Diabetes Endocrinol. 2017 Feb;5(2):134-142. doi: 10.1016/S2213-8587(16)30046-8. Epub 2016 Jun 23.
8
Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.静脉注射甲泼尼龙脉冲治疗重度格雷夫斯眼病的血压特征和 N 端脑利钠肽前体动态变化。
Int J Mol Sci. 2018 Sep 26;19(10):2918. doi: 10.3390/ijms19102918.
9
Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.甲泼尼龙治疗前后活动性格雷夫斯眼眶病患者血清中肝细胞生长因子（HGF）和白细胞介素-8（IL-8）的浓度。
J Endocrinol Invest. 2016 Jan;39(1):63-72. doi: 10.1007/s40618-015-0322-7. Epub 2015 Jun 11.
10
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.他汀类药物治疗格雷夫斯眼病（STAGO）：一项 2 期、开放标签、适应性、单中心、随机临床试验。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):733-742. doi: 10.1016/S2213-8587(21)00238-2. Epub 2021 Sep 27.

引用本文的文献

1
Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy.甲氨蝶呤联合减量或全量糖皮质激素治疗活动期、中重度格雷夫斯眼眶病。
Eur Thyroid J. 2022 Aug 24;11(5). doi: 10.1530/ETJ-22-0017. Print 2022 Oct 1.
2
Current concepts regarding Graves' orbitopathy.当前关于格雷夫斯眼病的概念。
J Intern Med. 2022 Nov;292(5):692-716. doi: 10.1111/joim.13524. Epub 2022 Jun 1.
3
Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.特罗特鲁单抗治疗甲状腺相关眼病的新疗法。

本文引用的文献

1
Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.早期使用类固醇节约剂治疗中重度活动期甲状腺眼病：逐步降级治疗策略。
Clin Endocrinol (Oxf). 2018 Dec;89(6):834-839. doi: 10.1111/cen.13834. Epub 2018 Sep 11.
2
Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.吗替麦考酚酯联合甲泼尼龙与单纯甲泼尼龙治疗活动期中重度格雷夫斯眼病（MINGO）的随机、观察者设盲、多中心临床试验
Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-8587(18)30020-2. Epub 2018 Jan 31.
3
Front Endocrinol (Lausanne). 2020 Dec 17;11:610337. doi: 10.3389/fendo.2020.610337. eCollection 2020.
4
Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?生物制剂是否会取代全身糖皮质激素成为甲状腺相关眼病的一线治疗方法？
Eur J Endocrinol. 2019 Nov;181(5):D27-D43. doi: 10.1530/EJE-19-0389.
Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.
联合免疫抑制和放疗治疗甲状腺眼病（CIRTED）：一项多中心、2×2 析因、双盲、随机对照试验。
Lancet Diabetes Endocrinol. 2018 Apr;6(4):299-309. doi: 10.1016/S2213-8587(18)30021-4. Epub 2018 Jan 31.
4
Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?替普罗单抗：治疗中重度活动性格雷夫斯眼眶病的新途径？
J Endocrinol Invest. 2017 Aug;40(8):885-887. doi: 10.1007/s40618-017-0717-8. Epub 2017 Jun 20.
5
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.2016年欧洲甲状腺协会/欧洲Graves眼病研究组Graves眼病管理指南
Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828. Epub 2016 Mar 2.
6
Extrathyroidal manifestations of Graves' disease: a 2014 update.格雷夫斯病的甲状腺外表现：2014年更新
J Endocrinol Invest. 2014 Aug;37(8):691-700. doi: 10.1007/s40618-014-0097-2. Epub 2014 Jun 10.
7
Efficacy and safety of orbital radiotherapy for graves' orbitopathy.眼眶放射治疗格雷夫斯眼病的疗效和安全性。
J Clin Endocrinol Metab. 2012 Nov;97(11):3857-65. doi: 10.1210/jc.2012-2758. Epub 2012 Sep 7.
8
Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.
N Engl J Med. 1989 Nov 16;321(20):1353-9. doi: 10.1056/NEJM198911163212002.